世界中でCOVID-19の評価における血液学のパラメータへの関心が高まっています。発表されたさまざまな研究は、パンデミックが市場に与える影響についての洞察を提供します。たとえば、2021年4月に国立医学図書館で発表された研究では、進行中のCOVID-19パンデミックが検査血液学のコミュニティに影響を与えたと述べられています。それにも関わらず、COVID-19に関連する血液学の研究は引き続き加速しており、疾患予後や結果を含む多くの目的のための検査血液学データの役割が確立されています。しかし、主要な市場プレーヤーによるパートナーシップなどの取り組みにより、市場の成長が期待されています。たとえば、2021年1月にF. ホフマン・ラ・ロッシュ社は、シスメックス株式会社とのグローバルビジネスパートナーシップ契約を締結し、ロシュがシスメックスの血液学検査製品（機器や試薬を含む）を販売できるようにしました。このような取り組みにより、市場は予測期間中に成長する可能性があります。

同様に、2022年7月に更新された世界止血連盟の報告によれば、全世界で1,125,000人以上の男性が遺伝性出血障害を抱えており、そのうち418,000人は最も診断されていない病気の重度のバージョンを持っています。早期診断と治療が血液細胞障害を持つ患者の生活の質を保護する最善の方法です。したがって、血液障害の増加する負担は、今後市場を促進する可能性があります。

血液学分析機器市場の動向

血液学分析装置産業の概要

• 1 イントロダクション

  • 1.1 調査の前提条件と市場の定義

  • 1.2 本調査の範囲

• 2 調査手法

• 3 エグゼクティブサマリー

• 4 市場ダイナミクス

  • 4.1 市場概要

  • 4.2 市場の促進要因

  • 4.3 市場の抑制要因

    • 4.3.1 ヘマトロジーアナライザーの高コスト

    • 4.3.2 時間のかかる厳しい規制政策

  • 4.4 業界魅力度 - ポーターのファイブフォース分析

    • 4.4.1 買い手・消費者の交渉力

    • 4.4.2 サプライヤーの交渉力

    • 4.4.3 新規参入の脅威

    • 4.4.4 代替品の脅威

    • 4.4.5 競合・競争状況の激しさ

• 5 市場セグメンテーション（市場規模別、金額、百万米ドル）

  • 5.1 製品タイプ別

    • 5.1.1 インスツルメンツ

      • 5.1.1.1 3 ヘマトロジーアナライザー
      • 5.1.1.2 5 ヘマトロジーアナライザー
      • 5.1.1.3 ポイントオブケア検査 ヘマトロジーアナライザー
      • 5.1.1.4 その他

    • 5.1.2 試薬

    • 5.1.3 サービス

  • 5.2 エンドユーザー別

    • 5.2.1 病院

    • 5.2.2 クリニカルラボラトリーズ

    • 5.2.3 研究機関

    • 5.2.4 その他のエンドユーザー

  • 5.3 地域別

    • 5.3.1 北米

      • 5.3.1.1 米国
      • 5.3.1.2 カナダ
      • 5.3.1.3 メキシコ

    • 5.3.2 ヨーロッパ

      • 5.3.2.1 ドイツ
      • 5.3.2.2 英国
      • 5.3.2.3 フランス
      • 5.3.2.4 イタリア
      • 5.3.2.5 スペイン
      • 5.3.2.6 その他のヨーロッパ

    • 5.3.3 アジア太平洋

      • 5.3.3.1 中国
      • 5.3.3.2 日本
      • 5.3.3.3 インド
      • 5.3.3.4 オーストラリア
      • 5.3.3.5 韓国
      • 5.3.3.6 その他のアジア太平洋

    • 5.3.4 中東・アフリカ

      • 5.3.4.1 GCC地域
      • 5.3.4.2 南アフリカ
      • 5.3.4.3 その他の中東・アフリカ

    • 5.3.5 南米

      • 5.3.5.1 ブラジル
      • 5.3.5.2 アルゼンチン
      • 5.3.5.3 その他の南米

• 6 競合情勢

  • 6.1 企業プロファイル

    • 6.1.1 Abbott Laboratories

    • 6.1.2 Beckman Coulter Inc. (Danaher Corporation)

    • 6.1.3 Bio-Rad Laboratories

    • 6.1.4 Boule Diagnostics AB

    • 6.1.5 F Hoffmann-La Roche Ltd

    • 6.1.6 Horiba Ltd

    • 6.1.7 Nihon Kohden Corporation

    • 6.1.8 Siemens Healthineers

    • 6.1.9 Sysmex Corporation

    • 6.1.10 Stratec Biomedical Systems (DIATRON)

    • 6.1.11 Ortho Clinical Diagnostics

    • 6.1.12 Accurex Biomedical Pvt. Ltd

• 7 市場機会と今後の動向

The Hematology Analyzers Market size is estimated at USD 6.23 billion in 2024, and is expected to reach USD 8.78 billion by 2029, growing at a CAGR of 7.10% during the forecast period (2024-2029).

There was an increasing focus on the hematology parameters for the assessment of COVID-19 around the world. Various research studies published provide insight into the effects of the pandemic on the market. For instance, in April 2021, a study published in the National Library of Medicine stated that the ongoing COVID-19 pandemic had an impact on the laboratory hematology community. Nevertheless, the pace of COVID-19 hematology-related research has continued to accelerate and has established the role of laboratory hematology data for many purposes including disease prognosis and outcome. However, initiatives such as partnerships by key market players are expected to increase the market growth. For instance, in January 2021, F. Hoffmann-La Roche AG signed a global business partnership agreement with Sysmex Corporation that allows Roche to distribute Sysmex hematology testing products, including instruments and reagents. Thus, with such initiatives, the market is likely to grow over the forecast period.

The major factors for the growth of the hematology analyzers market include the rising burden of blood disorders, increasing technological advancements, and rising adoption rates of automated hematology instruments. Blood disorders have become a global health issue with different causes and are associated with high mortality. Blood disorders, such as anemia, blood cancers, hemorrhagic conditions, and infections in the blood, affect millions of people each year across all age groups. According to the Australian Government, Department of Health and Aged Care report in 2022, more than 330,000 affected infants are born each year (83% sickle cell disorders and 17% thalassaemias), around 7% of pregnant women are carriers of hemoglobin disorders, and over 1% of couples are at risk at a global level.

Similarly, according to the World Federation of Hemophilia report updated July 2022, more than 1,125,000 men worldwide have an inherited bleeding disorder, and 418,000 of those have a severe version of the most undiagnosed disease. Early diagnosis and treatment are the best ways to protect the quality of life of a patient with a blood cell disorder. Hence, the increasing burden of blood disorders is likely to drive the market in the future.

Product launches are another factor in market growth. For instance, in July 2022, CellaVision launched DIFF-Line. CellaVision DC-1 is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. Thus, such product launches are expected to increase market growth over the forecast period.

However, the high cost of hematology analyzers and time-consuming and stringent regulatory policies associated with the same is restraining the overall market growth.

Hematology Analyzers Market Trends

3 Part Hematology Analyzer is the Segment by Instruments Expected to Hold Significant Market Share Over the Forecast Period

A 3-part differential cell counter uses Coulter's Principle to find the size and volume of the cell. The sample is lysed and dissolved into an electrolyte solution in a container, which also holds a smaller container. 3-part hematology analyzer systems are ideally suited for physician office laboratories, clinics, and small hospitals that perform moderately complex testing. There is increased interest in 5-part hematology analyzers, however, 3-part hematology analyzers are more cost-effective for routine hematological tests. Furthermore, with advancements in technology and the availability of these instruments across the world coupled with affordability the market is projected to have notable growth. Similarly, convenience and accurate results are the two major reasons driving the growth of the segment over the forecast period.

Ebola Virus is a serious fatal condition that is caused by 4 different species of virus in human and non-human primates. The virus can spread to people through direct contact with the blood, and body fluids, of the person who is having or died from the Ebola virus. It causes hemorrhagic fever which leads to internal and external bleeding and affects multiple organs. The Ebola outbreak in Uganda was declared on September 20, 2022, and it has already spread to seven regions (Kasanda, Kyegegwa, Bunyangabu, and Kagadi districts beyond the original epicenter in Mubende district, and then to Kampala City and Wakiso). Thus, such outbreaks require proper diagnosis to control the spread of the disease which is expected to increase the demand for 3 part hematology analyzer during the forecast period.

Initiatives such as product launches are another factor in market growth. For instance, in April 2022 Sysmex Europe launched its new three-part differential automated hematology analyzer, XQ-320. It is a robust device with low demands for sample volume, bench space, and maintenance in Europe. Thus, the abovementioned factors are expected to increase market growth during the forecast period.

North America is Expected to Hold Significant Market Share Over the Forecast Period

The market for hematology analyzers in the North American region is growing at a steady pace. This can be attributed to the increasing burden of blood disorders and the growth in the adoption of hematology analyzers by the diagnostic industry. For instance, according to the American Society of Hematology, anemia, which is a common disorder, affects more than three million Americans, particularly women of 'childbearing age. According to the Leukemia and Lymphoma Society in 2021, every three minutes, a person in the United States is diagnosed with blood cancer. An estimated 186,400 people in the United States were diagnosed with leukemia, lymphoma, or melanoma in 2021.

Furthermore, many centers in the state are international leaders in the diagnosis and treatment of blood diseases and collaborate in many research projects to improve diagnosis and treatment options for blood diseases. Many market players are present in the country and are continuously focusing on the development and introduction of novel products. In February 2021 Beckman Coulter launched the DxH 560 AL, a tabletop hematology analyzer designed to reduce time and resource constraints faced by small- to mid-sized laboratories. Similarly, in November 2021, Avricore Health Inc signed a non-exclusive pilot supplier distribution agreement in Canada between HealthTab Inc., a wholly-owned subsidiary, and Abbott, the global healthcare company, concerning the handheld blood chemistry analyzer i-STAT Alinity. Thus, such product launches are expected to increase the adoption of hematology analyzers in the region.

These factors drive the demand for hematology analyzers in the North American region over the forecast period.

Hematology Analyzers Industry Overview

The hematology analyzers market is a fragmented market owing to the presence of various market players. Some of the market players are Abbott Laboratories, Beckman Coulter Inc. (Danaher Corporation), Bio-Rad Laboratories, Boule Diagnostics AB, F Hoffmann-La Roche Ltd, Hobira Ltd, Nihon Kohden Corporation, Mindray Medical International Limited (Shenzhen Mindray Bio-Medical Electronics Co. Ltd), Siemens Healthineers, and Sysmex Corporation.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

• 1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition

  • 1.2 Scope of the Study

• 2 RESEARCH METHODOLOGY

• 3 EXECUTIVE SUMMARY

• 4 MARKET DYNAMICS

  • 4.1 Market Overview

  • 4.2 Market Drivers

    • 4.2.1 Rising Burden of Blood Disorders

    • 4.2.2 Increasing Technological Advancements and Rising Adoption Rates of Automated Hematology Instruments

  • 4.3 Market Restraints

    • 4.3.1 High Cost of Hematology Analyzers

    • 4.3.2 Time-consuming and Stringent Rregulatory Policies

  • 4.4 Industry Attractiveness - Porter's Five Forces Analysis

    • 4.4.1 Bargaining Power of Buyers/Consumers

    • 4.4.2 Bargaining Power of Suppliers

    • 4.4.3 Threat of New Entrants

    • 4.4.4 Threat of Substitute Products

    • 4.4.5 Intensity of Competitive Rivalry

• 5 MARKET SEGMENTATION (Market Size by Value - USD million)

  • 5.1 By Product Type

    • 5.1.1 Instruments

      • 5.1.1.1 3 Part Hematology Analyzer
      • 5.1.1.2 5 Part Hematology Analyzer
      • 5.1.1.3 Point-of-care Testing Hematology Analyzers
      • 5.1.1.4 Others

    • 5.1.2 Reagents

    • 5.1.3 Services

  • 5.2 By End User

    • 5.2.1 Hospitals

    • 5.2.2 Clinical Laboratories

    • 5.2.3 Research Institutes

    • 5.2.4 Other End Users

  • 5.3 Geography

    • 5.3.1 North America

      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico

    • 5.3.2 Europe

      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe

    • 5.3.3 Asia-Pacific

      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific

    • 5.3.4 Middle East and Africa

      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa

    • 5.3.5 South America

      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

• 6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles

    • 6.1.1 Abbott Laboratories

    • 6.1.2 Beckman Coulter Inc. (Danaher Corporation)

    • 6.1.3 Bio-Rad Laboratories

    • 6.1.4 Boule Diagnostics AB

    • 6.1.5 F Hoffmann-La Roche Ltd

    • 6.1.6 Horiba Ltd

    • 6.1.7 Nihon Kohden Corporation

    • 6.1.8 Siemens Healthineers

    • 6.1.9 Sysmex Corporation

    • 6.1.10 Stratec Biomedical Systems (DIATRON)

    • 6.1.11 Ortho Clinical Diagnostics

    • 6.1.12 Accurex Biomedical Pvt. Ltd

• 7 MARKET OPPORTUNITIES AND FUTURE TRENDS